Compilation of top learnings on and approaches to implementing HIV/SRH integration in sub-Saharan Africa, drawn from literature reviews, qualitative interviews, and an analysis of policy requirements for PrEP and family planning providers.
HIV & Sexual and Reproductive Health Integration
Exploring Integration of Family Planning and HIV Services
A literature review to identify existing knowledge on barriers and enablers to the integration of HIV and family planning services in sub-Saharan Africa, in order to understand the feasibility of providing existing and new HIV prevention options and services in family planning settings.
Voluntary Medical Male Circumcision for HIV Prevention (VMMC): An introductory factsheet
This introductory 2-page document explains how VMMC works, reviews the scientific evidence behind it, and outlines key advocacy issues for implementing it.
HVTN 702 and the Quest for Vaccine
One of the most anticipated HIV vaccine efficacy trials in the field—HVTN 702, or Uhambo—stopped vaccinations early after a scheduled review showed the vaccine did not offer protection.
The trial team will continue to follow participants over the next year to monitor safety and answer urgent questions raised by the trial results. In this episode of Px Pulse, HVTN 702 Protocol Co-chair and AVAC Board Member Linda-Gail Bekker explores what the trial team hopes to learn during the follow-up period and how these answers might impact the ongoing pursuit for an HIV vaccine. AVAC’s Regional Stakeholder Engagement Advisor Nandisile Luthuli also joins the conversation to shed light on the trial team’s plans for continuing community engagement, and AVAC’s Director of Research Engagement, Stacey Hannah, talks about the successes of the trial.
Vaccine Efficacy Trials Pipeline
This infographic shows a timeline for each of the three major vaccine efficacy trials proposed or underway now.
Vaccines Research Pipeline
This graphic shows the many types of Vaccines undergoing research, categorized by the immune response they are designed to elicit—broadly neutralizing antibodies, non-neutralizing antibodies, T-cell responses or a combination of these.
Frequently Asked Questions (FAQ) – Index Testing
Index testing, a PEPFAR initiative that tracks the contacts of people who test positive for HIV, has potential benefits when done ethically. But index testing is presently being aggressively implemented in ways that cause harm, increase risk of violence and undermine people’s rights to consent, confidentiality and safety. Changes must be made to protect individuals and foster community trust in their healthcare system. For activists and advocates attending PEPFAR in-country retreats, this FAQ provides background and advocacy priorities.
2020 Global Targets for Prevention Will Not Be Met: Now What?
With unmet UNAIDS “Fast-Track” targets for ending the epidemic now a reality, the field faces the sobering truth that we’ve been striving towards the 90-90-90 treatment targets without the same enthusiasm, focus and commitment to primary prevention targets.
In this episode of Px Pulse, AVAC’s Emily Bass and lead author of our report Now What? talks about AVAC’s blueprint for course correcting—bold leadership, smart target-setting for HIV prevention research and implementation, and multilayered prevention programs that are centered around people. She explains why the epidemic needs a sustained response and how leaders from the highest level down to the grassroots can demand accountability and reject a “business as usual” approach.
What’s All the Fuss About F/TAF? A Trailer for Action in 2020
What’s all the fuss about F/TAF for oral PrEP? The US Food and Drug Administration (FDA) approved drug maker Gilead’s Descovy (also known as F/TAF) as daily oral PrEP in October 2019, with one notable caveat: the label excluded those who are at risk from “receptive vaginal sex”, indicating that more data is needed for the drug to be approved as HIV prevention for cisgender women. The FDA’s supplemental approval requires Gilead to conduct safety and efficacy trial in cisgender women on a timeline that aims for data by 2025.
In the aftermath of this approval, there are questions about the differences between these two forms of PrEP, what contribution F/TAF might make to the pipeline of prevention, and the vital role of stakeholder engagement as Gilead drafts the study protocol for a trial of F/TAF in women. We explore all this and more in this episode of Px Pulse.
Materials
AVAC Report 2019: One-pager
Each year, the AVAC Report frames the most pressing advocacy issues facing the HIV response. At the threshold of 2020, it’s clear that global goals for HIV prevention will miss the mark by a long shot. Now what?
This is a one-pager summarizing AVAC’s priorities for 2020. To download the full Report or see all its graphics, visit report.avac.org.